Abbott India Q4 Results Review - Highest-Ever Ebitda Margins: Axis Securities

Axis Securities Report

Abbott India Ltd. reported revenue growth of 7.1% YoY and outpaced the IPM’s growth of 6% in Q4 FY24. While chronic growth halved to 6%, acute therepy segment continued its muted performance in the last quarter.

Abbott India achieved higher sales growth on accoutnt of a change in product mix, and a higher share of the antidiabetics, vitamins, and Hormones which reported YoY growth of 8.3%, 10.8% and 13.3% respectively.

However, this was partially offset by Mixtard and Novomix, which recorded -0.4% growth and 10.8% de-growth YoY leading to high single-digit topline growth.

In addition, growth in other key therapies such as anti-infective (+3.5% YoY) and central nervous system (+1.4% YoY) was below IPM growth.

Duphaston (gynaecology) sales stabilised at Rs 395 crore (Source: AIOCD) in Q4 FY24, registering a growth of 4.2% YoY.

Click on the attachment to read the full report:

DISCLAIMER

This report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.